Abstract
G protein-coupled receptors (GPCRs) are the largest family of integral membrane proteins. With more than 800 members, they play an important role in mediating cell signaling across the cytoplasmic membrane to activate downstream proteins such as G proteins and β-arrestins. The first GPCR crystal structure determined was bovine rhodopsin in 2000. Since 2007, there have been more than 300 crystal structures and 12 cryo-EM structures published, while those numbers keep growing. This article is aimed at providing some historical perspectives of this so-called golden age of GPCR structural biology, as well as some new insights from the structures into the mechanism of GPCR signaling at molecular and atomic levels.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Appleton KM, et al. Development of inhibitors of heterotrimeric Galphai subunits. Bioorg Med Chem. 2014;22(13):3423–34.
Ayoub MA. Small molecules targeting heterotrimeric G proteins. Eur J Pharmacol. 2018;826:169–78.
Ayoub MA, et al. Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit. J Biol Chem. 2009;284(42):29136–45.
Ayturk UM, et al. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Hum Genet. 2016;98(4):789–95.
Azzi M, et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A. 2003;100(20):11406–11.
Beaulieu JM, et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–73.
Bianco P, et al. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest. 1998;101(8):1737–44.
Bonacci TM, et al. Differential targeting of Gbetagamma-subunit signaling with small molecules. Science. 2006;312(5772):443–6.
Bond RA, et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature. 1995;374(6519):272–6.
Chidiac P, et al. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol. 1994;45(3):490–9.
Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci. 1999;20(7):279–86.
Dixon RA, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature. 1986;321(6065):75–9.
Dore AS, et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 2014;511(7511):557–62.
Eilers M, et al. Comparison of class A and D G protein-coupled receptors: common features in structure and activation. Biochemistry. 2005;44(25):8959–75.
Francis JH, et al. GNAQ mutations in diffuse and solitary choroidal hemangiomas. Ophthalmology. 2018;126(5):759–63.
Freissmuth M, et al. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol. 1996;49(4):602–11.
Granier S, et al. Structure of the delta-opioid receptor bound to naltrindole. Nature. 2012;485(7398):400–4.
Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8.
Henderson R, Unwin PN. Three-dimensional model of purple membrane obtained by electron microscopy. Nature. 1975;257(5521):28–32.
Hohenegger M, et al. Gsalpha-selective G protein antagonists. Proc Natl Acad Sci U S A. 1998;95(1):346–51.
Hollenstein K, et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature. 2013;499(7459):438–43.
Hurowitz EH, et al. Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res. 2000;7(2):111–20.
Jazayeri A, et al. Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature. 2017;548(7665):122.
Johnson RL, et al. Identification and targeted gene disruption of cAR3, a cAMP receptor subtype expressed during multicellular stages of Dictyostelium development. Genes Dev. 1993;7(2):273–82.
Kapoor N, et al. Structural evidence for a sequential release mechanism for activation of heterotrimeric G proteins. J Mol Biol. 2009;393(4):882–97.
Klebanov N, et al. Use of targeted next-generation sequencing to identify activating hot spot mutations in cherry angiomas. JAMA Dermatol. 2019;155(2):211–5.
Klein PS, et al. A chemoattractant receptor controls development in Dictyostelium discoideum. Science. 1988;241(4872):1467–72.
Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther. 2004;103(1):21–80.
Landau EM, Rosenbusch JP. Lipidic cubic phases: a novel concept for the crystallization of membrane proteins. Proc Natl Acad Sci U S A. 1996;93(25):14532–5.
Landis CA, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340(6236):692–6.
Liu Y, Dilger JP. Decamethonium is a partial agonist at the nicotinic acetylcholine receptor. Synapse. 1993;13(1):57–62.
Lodder EM, et al. GNB5 mutations cause an autosomal-recessive multisystem syndrome with Sinus Bradycardia and cognitive disability. Am J Hum Genet. 2016;99(3):704–10.
Lohmann K, et al. Novel GNB1 mutations disrupt assembly and function of G protein heterotrimers and cause global developmental delay in humans. Hum Mol Genet. 2017;26(6):1078–86.
Lokits AD, et al. Tracing the evolution of the heterotrimeric G protein alpha subunit in Metazoa. BMC Evol Biol. 2018;18(1):51.
Manglik A, et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature. 2012;485(7398):321–6.
Martins L, et al. Computational analysis for GNAQ mutations: New insights on the molecular etiology of Sturge-Weber syndrome. J Mol Graph Model. 2017;76:429–40.
Nathans J, Hogness DS. Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine rhodopsin. Cell. 1983;34(3):807–14.
Nielsen TB, et al. Characteristics of the guanine nucleotide regulatory component of adenylate cyclase in human erythrocyte membranes. Biochim Biophys Acta. 1980;629(1):143–55.
Nishimura A, et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci U S A. 2010;107(31):13666–71.
Northup JK, et al. Purification of the regulatory component of adenylate cyclase. Proc Natl Acad Sci U S A. 1980;77(11):6516–20.
Oka Y, et al. The fifth class of Galpha proteins. Proc Natl Acad Sci U S A. 2009;106(5):1484–9.
Palczewski K, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289(5480):739–45.
Park JH, et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature. 2008;454(7201):183–7.
Petrovski S, et al. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. Am J Hum Genet. 2016;98(5):1001–10.
Prevost GP, et al. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Res. 2006;66(18):9227–34.
Pupo AS, et al. Recent updates on GPCR biased agonism. Pharmacol Res. 2016;112:49–57.
Rasmussen SG, et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature. 2011a;469(7329):175–80.
Rasmussen SG, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature. 2011b;477(7366):549–55.
Roux KH, et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci U S A. 1998;95(20):11804–9.
Samama P, et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 1993;268(7):4625–36.
Scheerer P, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature. 2008;455(7212):497–502.
Schrage R, et al. The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun. 2015;6(6):10156.
Shamseldin HE, et al. GNB5 mutation causes a novel neuropsychiatric disorder featuring attention deficit hyperactivity disorder, severely impaired language development and normal cognition. Genome Biol. 2016;17(1):195.
Smrcka AV. G protein betagamma subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci. 2008;65(14):2191–214.
Sondek J, et al. Crystal structure of a G-protein beta gamma dimer at 2.1A resolution. Nature. 1996;379(6563):369–74.
Soong BW, et al. Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-Tooth disease. Am J Hum Genet. 2013;92(3):422–30.
Spiegel AM. G protein defects in signal transduction. Horm Res. 2000;53(Suppl 3):17–22.
Spiegelberg BD, Hamm HE. G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. J Biol Chem. 2005;280(50):41769–76.
Surve CR, Lehmann D, Smrcka AV. A chemical biology approach demonstrates G protein betagamma subunits are sufficient to mediate directional neutrophil chemotaxis. J Biol Chem. 2014;289(25):17791–801.
Syrovatkina V, et al. Regulation, signaling, and physiological functions of G-proteins. J Mol Biol. 2016;428(19):3850–68.
Szabo V, et al. p.Gln200Glu, a putative constitutively active mutant of rod alpha-transducin (GNAT1) in autosomal dominant congenital stationary night blindness. Hum Mutat. 2007;28(7):741–2.
Szczaluba K, et al. Novel GNB1 de novo mutation in a patient with neurodevelopmental disorder and cutaneous mastocytosis: clinical report and literature review. Eur J Med Genet. 2018;61(3):157–60.
Tan Q, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science. 2013;341(6152):1387–90.
Unger VM, et al. Arrangement of rhodopsin transmembrane alpha-helices. Nature. 1997;389(6647):203–6.
Vaidehi N, Grisshammer R, Tate CG. How can mutations thermostabilize G-protein-coupled receptors? Trends Pharmacol Sci. 2016;37(1):37–46.
Vincent A, et al. Biallelic Mutations in GNB3 cause a unique form of autosomal-recessive congenital stationary night blindness. Am J Hum Genet. 2016;98(5):1011–9.
Wang W, Qiao Y, Li Z. New Insights into Modes of GPCR Activation. Trends Pharmacol Sci. 2018;39(4):367–86.
Warne T, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature. 2008;454(7203):486–91.
Weinstein LS, Shenker A. G protein mutations in human disease. Clin Biochem. 1993;26(5):333–8.
Xiang J, et al. Successful strategies to determine high-resolution structures of GPCRs. Trends Pharmacol Sci. 2016;37(12):1055–69.
Xie K, et al. NF1 is a direct G protein effector essential for opioid signaling to Ras in the Striatum. Curr Biol. 2016;26(22):2992–3003.
Xiong XF, et al. Structure-activity relationship studies of the natural product Gq/11 protein inhibitor YM-254890. Chem Med Chem. 2019;14:865–70.
Zhang H, et al. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell. 2015;161(4):833–44.
Acknowledgments
This work is supported by National Key Research and Development Program of China (2018YFC1004704 and 2017YFC1001303), NSFC-CAS Joint Fund for Research Based on Large-Scale Scientific Facilities (U1632132), and NSFC General Program (31670849). Given the space limitation of the article, the authors regret the omission of many excellent publications on the subject matter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chen, Y., Xia, Y., Cao, Y. (2019). A Historical Perspective of G Protein-Coupled Receptor Structural Biology. In: Cao, Y. (eds) Advances in Membrane Proteins. Springer, Singapore. https://doi.org/10.1007/978-981-13-9077-7_2
Download citation
DOI: https://doi.org/10.1007/978-981-13-9077-7_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9076-0
Online ISBN: 978-981-13-9077-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)